" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Announces Evaluation of Genedrive® for Pathogen Detection

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Epistem in cooperative agreement with the US Air Force and with Johns Hopkins University.

Epistem Holdings Plc has announced that it has entered into a cooperative agreement with the US Air Force alongside an agreement with Johns Hopkins University (Advanced Physics Laboratory), to undertake the combat evaluation of Epistem's Genedrive® handheld molecular device for pathogen detection.

The agreement will commence immediately and provides $0.6m (GBP 0.4m) over 5 months to develop and evaluate Genedrive® for the identification of three known disease pathogens.

Successful completion of the combat evaluation programme will secure ongoing investment for the development of Genedrive® as a handheld pathogen detection unit for the US Department of Defence.

Preparations for the 2014 launch of the company's first Genedrive® disease test in Tuberculosis continue, with progress to resolve the earlier reported software and firmware issues now nearing completion.

Whilst unit testing is ongoing, preparations are being made for the commencement of final stage clinical trials in support of Indian regulatory approval.

2014 plans to undertake clinical trials with the Foundation for Innovative New Diagnostics (FIND) have also commenced as a forerunner to a potential WHO recommendation in 2015.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem, Global Health Investment Fund Sign Collaborative Funding Agreement
Agreement will see GHIF support the roll-out of Epistem's Genedrive® molecular diagnostic platform.
Wednesday, July 23, 2014
Epistem Announces Executive Board Appointments
Dr Allan Brown joins the Board as Chief Operating Officer of the Diagnostics division of the Company, with effect from 1st February, 2014.
Monday, January 27, 2014
Epistem Tuberculosis Test Gains CE-IVD Registration
Epistem to place its TB test and Genedrive™ units for sale in the EEA member state markets.
Thursday, July 05, 2012
Epistem Signs Tuberculosis Channel Partner Agreement
Company signs sales and marketing agreement for rapid molecular test for TB.
Tuesday, March 06, 2012
Epistem Holdings Announce £2.8 Million Cash Placing
Company to use the net proceeds to accelerate the development and commercialization of Genedrive™.
Tuesday, November 29, 2011
Scientific News
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!